James B Bussel, M.D.

Pediatric Hematology-Oncology
James Bussel

Named one of New York Magazine's Best Doctors, 2012
Named one of New York's Super Doctors, 2012


Dr. James Bussel received his medical degree (M.D.) from Columbia University's College of Physicians and Surgeons after completing a B.S. at Yale University.  He completed his residency in pediatrics at Cincinnati Children's Hospital in Ohio, returning to New York City to undertake a joint fellowship in Pediatric Hematology/Oncology at Memorial Sloan-Kettering Cancer Center and NewYork-Presbyterian Hospital where he was chief fellow in 1980-81.   He is board certified in Pediatrics and in Pediatric Hematology/Oncology.
 
Research
 
In 1981, the Platelet Disorders Center initiated the first studies of intravenous gammaglobulin in the treatment of ITP in the United States. This was followed by studies in ITP with IV anti-D (Winrho) beginning in 1987, rituximab in 2000, and the newly licensed thrombopoietic agents in 2002.   More than two hundred publications on ITP in children and adults have followed, including six first or second authored articles in the New England Journal of Medicine and two in the Lancet. In 2003, Dr. Bussel was selected as one of 5 representatives of the American Society of Hematology (SPARKII) to meet with representatives of the NIH to plan research directions in hematology for the future.

Adults have worse ITP than do children. Therefore, trials and studies at the center have increasingly included them with the first publication on the treatment of adults in 1983. The center is the country's and the world's leader in clinical trials of refractory ITP in exploring novel agents including those that modulate the immune system.
 
Another area of Dr. Bussel's special expertise is the treatment of fetuses affected by alloimmune thrombocytopenia. This is a platelet incompatibility between the parents that affects the fetus. Treatment can be given during the pregnancy to the mother to increase the platelet count in the fetus, prevent a fetal brain hemorrhage, and allow for a healthy baby to be born whose thrombocytopenia will then disappear within weeks.

Insurances

Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please feel free to contact this physician or this physician's practice as they may have individual contracts not included on this site.

  • AETNA [PPO]
  • AETNA [Medicare]
  • AETNA [HMO]
  • Aetna - Weill Cornell [POS]
  • Affinity Essential
  • Affinity Health Plan
  • Blue Priority Network
  • CIGNA
  • Emblem Select Care
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [Pathway X Enhanced]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [Pathway X]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Fidelis Care
  • Health First
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Insurance Plan of NY (HIP)
  • Health Plus - Amerigroup [CHP]
  • Health Plus - Amerigroup
  • Health Republic
  • Medicaid
  • Medicare
  • Medicare [Medicare]
  • Oscar
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Liberty]
  • Oxford Health Plans [Freedom]
  • POMCO
  • Rockefeller University - CoreSource
  • UHC Compass
  • United Empire
  • United Health Care [Medicare]
  • United Health Care [Community Plan]
  • United Health Care
  • VNSNY CHOICE Medicare [HMO]

Publications

  1. Patel VL, Mahévas M, Lee SY, Stasi R, Cunningham-Rundles S, Godeau B, Kanter J, Neufeld E, Taube T, Ramenghi U, Shenoy S, Ward MJ, Mihatov N, Patel VL,
    Bierling P, Lesser M, Cooper N, Bussel JB. Outcome at 5 years following response to rituximab therapy in children and adults with immune thrombocytopenia (ITP). Blood. 2012 May 7. [Epub ahead of print] PubMed PMID: 22566601.
  2. Bussel JB, Cines DB. Avoiding intuxication. Blood. 2012 Apr 19;119(16):3648-9.
    PubMed PMID: 22517870.
  3. Arnason JE, Campigotto F, Neuberg D, Bussel JB. Abnormalities in IgA and IgM are associated with treatment-resistant ITP. Blood. 2012 Apr 6. [Epub ahead of print] PubMed PMID: 22490683.
  4. Psaila B, Bussel JB, Linden MD, Babula B, Li Y, Barnard MR, Tate C, Mathur K,
    Frelinger AL, Michelson AD. In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. Blood. 2012 Apr 26;119(17):4066-72. Epub 2012 Jan 31. PubMed PMID: 22294727; PubMed Central PMCID: PMC3350368.
  5. Puga I, Cols M, Barra CM, He B, Cassis L, Gentile M, Comerma L, Chorny A, Shan
    M, Xu W, Magri G, Knowles DM, Tam W, Chiu A, Bussel JB, Serrano S, Lorente JA,
    Bellosillo B, Lloreta J, Juanpere N, Alameda F, Baró T, de Heredia CD, Torán N,
    Català A, Torrebadell M, Fortuny C, Cusí V, Carreras C, Diaz GA, Blander JM,
    Farber CM, Silvestri G, Cunningham-Rundles C, Calvillo M, Dufour C, Notarangelo LD, Lougaris V, Plebani A, Casanova JL, Ganal SC, Diefenbach A, Aróstegui JI, Juan M, Yagüe J, Mahlaoui N, Donadieu J, Chen K, Cerutti A. B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nat Immunol. 2011 Dec 25;13(2):170-80. doi: 10.1038/ni.2194. PubMed PMID: 22197976; PubMed Central PMCID: PMC3262910.
  6. Sanborn KB, Mace EM, Rak GD, Difeo A, Martignetti JA, Pecci A, Bussel JB,
    Favier R, Orange JS. Phosphorylation of the myosin IIA tailpiece regulates single
    myosin IIA molecule association with lytic granules to promote NK-cell cytotoxicity. Blood. 2011 Nov 24;118(22):5862-71. PubMed PMID: 22123909; PubMed Central PMCID: PMC3228501.
  7. Cines DB, Blajchman MA, High KA, Bussel JB; for the State-of-the Science
    Symposium Hemostasis-Thrombosis Committee. Clinical trial opportunities in
    hemostasis and thrombosis: NHBLI State-of-the-science symposium. Am J Hematol. 2011 Oct 21. doi: 10.1002/ajh.22225. [Epub ahead of print] PubMed PMID: 22120890.
  8. Pacheco LD, Berkowitz RL, Moise KJ Jr, Bussel JB, McFarland JG, Saade GR.
    Fetal and neonatal alloimmune thrombocytopenia: a management algorithm based on risk stratification. Obstet Gynecol. 2011 Nov;118(5):1157-63. PubMed PMID: 22015886.
  9. Meyer R, Bussel JB. Consider thrombotic microangiopathy in pediatric and
    hematopoietic stem cell transplant patients. Oncology (Williston Park). 2011
    Sep;25(10):920-1, 924. PubMed PMID: 22010389.
  10. Despotovic JM, Lambert MP, Herman JH, Gernsheimer TB, McCrae KR, Tarantino
    MD, Bussel JB. RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME). Transfusion. 2012 May;52(5):1126-1136. doi: 10.1111/j.1537-2995.2011.03384.x. Epub 2011 Oct 7. PubMed PMID: 21981825.
  11. Gobert D, Bussel JB, Cunningham-Rundles C, Galicier L, Dechartres A, Berezne
    A, Bonnotte B, DeRevel T, Auzary C, Jaussaud R, Larroche C, LeQuellec A, Ruivard
    M, Seve P, Smail A, Viallard JF, Godeau B, Hermine O, Michel M. Efficacy and
    safety of rituximab in common variable immunodeficiency-associated immune
    cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol. 2011
    Nov;155(4):498-508. doi: 10.1111/j.1365-2141.2011.08880.x. Epub 2011 Oct 8.
    PubMed PMID: 21981575.
  12. Ghanima W, Junker P, Hasselbalch HC, Boiocchi L, Geyer JT, Feng X,
    Gudbrandsdottir S, Orazi A, Bussel JB. Fibroproliferative activity in patients
    with immune thrombocytopenia (ITP) treated with thrombopoietic agents. Br J
    Haematol. 2011 Oct;155(2):248-55. doi: 10.1111/j.1365-2141.2011.08845.x. Epub
    2011 Sep 9. PubMed PMID: 21902682.
  13. Boiocchi L, Orazi A, Ghanima W, Arabadjief M, Bussel JB, Geyer JT.
    Thrombopoietin receptor agonist therapy in primary immune thrombocytopenia is
    associated with bone marrow hypercellularity and mild reticulin fibrosis but not
    other stromal abnormalities. Mod Pathol. 2012 Jan;25(1):65-74. doi:
    10.1038/modpathol.2011.128. Epub 2011 Aug 12. PubMed PMID: 21841770.
  14. Sarpatwari A, Bussel JB, Ahmed M, Erqou S, Semple JW, Newland AC, Bennett D,
    Pharoah P, Provan D. Single nucleotide polymorphism (SNP) analysis demonstrates a significant association of tumour necrosis factor-alpha (TNFA) with primary immune thrombocytopenia among Caucasian adults. Hematology. 2011 Jul;16(4):243-8. PubMed PMID: 21756542.
  15. Rayment R, Brunskill SJ, Soothill PW, Roberts DJ, Bussel JB, Murphy MF.
    Antenatal interventions for fetomaternal alloimmune thrombocytopenia. Cochrane
    Database Syst Rev. 2011 May 11;(5):CD004226. Review. PubMed PMID: 21563140.
  16. Bussel JB, Buchanan GR, Nugent DJ, Gnarra DJ, Bomgaars LR, Blanchette VS,
    Wang YM, Nie K, Jun S. A randomized, double-blind study of romiplostim to
    determine its safety and efficacy in children with immune thrombocytopenia.
    Blood. 2011 Jul 7;118(1):28-36. Epub 2011 Apr 18. PubMed PMID: 21502541.
  17. Barsam SJ, Psaila B, Forestier M, Page LK, Sloane PA, Geyer JT, Villarica GO,
    Ruisi MM, Gernsheimer TB, Beer JH, Bussel JB. Platelet production and platelet
    destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. Blood. 2011 May 26;117(21):5723-32. Epub 2011 Mar 9. PubMed PMID: 21389318; PubMed Central PMCID: PMC3110029.
  18. Bussel JB, Pinheiro MP. Eltrombopag. Cancer Treat Res. 2011;157:289-303.
    Review. PubMed PMID: 21052963.
  19. Vinograd CA, Bussel JB. Antenatal treatment of fetal alloimmune thrombocytopenia: a current perspective. Haematologica. 2010 Nov;95(11):1807-11. PubMed PMID: 21037327; PubMed Central PMCID: PMC2966900.
  20. Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, Arning M, Stone NL,
    Bussel JB. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011 Jan 29;377(9763):393-402. Epub 2010 Aug 23. Erratum in: Lancet. 2011 Jan 29;377(9763):382. PubMed PMID: 20739054
  21. Bao W, Bussel JB, Heck S, He W, Karpoff M, Boulad N, Yazdanbakhsh K. Improved
    regulatory T-cell activity in patients with chronic immune thrombocytopenia
    treated with thrombopoietic agents. Blood. 2010 Nov 25;116(22):4639-45. Epub 2010 Aug 5. PubMed PMID: 20688957; PubMed Central PMCID: PMC2996119.
  22. He B, Santamaria R, Xu W, Cols M, Chen K, Puga I, Shan M, Xiong H, Bussel JB,
    Chiu A, Puel A, Reichenbach J, Marodi L, Döffinger R, Vasconcelos J, Issekutz A,
    Krause J, Davies G, Li X, Grimbacher B, Plebani A, Meffre E, Picard C,
    Cunningham-Rundles C, Casanova JL, Cerutti A. The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat Immunol. 2010 Sep;11(9):836-45. Epub 2010 Aug 1. PubMed PMID: 20676093; PubMed Central PMCID: PMC3047500.
  23. Rabin DU, Kuter DJ, Liebman HA, Bussel JB. What do healthcare providers ask
    their patients with immune thrombocytopenia? Am J Hematol. 2010 Aug;85(8):629-31. PubMed PMID: 20658595.
  24. Ruisi MM, Psaila B, Ward MJ, Villarica G, Bussel JB. Stability of measurement
    of the immature platelet fraction. Am J Hematol. 2010 Aug;85(8):622-4. PubMed
    PMID: 20658593.
  25. Ghanima W, Bussel JB. Thrombopoietic agents in immune thrombocytopenia. Semin Hematol. 2010 Jul;47(3):258-65. Review. PubMed PMID: 20620437.
  26. Bussel JB, Kuter DJ. New thrombopoietic agents: introduction. Semin Hematol.
    2010 Jul;47(3):211. PubMed PMID: 20620430.
  27. Vincent LM, Gilbert F, DiPace JI, Ciccone C, Markello TC, Jeong A, Dorward H,
    Westbroek W, Gahl WA, Bussel JB, Huizing M. Novel 47.5-kb deletion in RAB27A
    results in severe Griscelli Syndrome Type 2. Mol Genet Metab. 2010 Sep;101(1):62-5. Epub 2010 Jun 10. PubMed PMID: 20591709; PubMed Central PMCID: PMC2922439.
  28. Bussel JB, Berkowitz RL, Hung C, Kolb EA, Wissert M, Primiani A, Tsaur FW,
    Macfarland JG. Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus. Am J Obstet Gynecol. 2010 Aug;203(2):135.e1-14. Epub 2010 May 21. PubMed PMID: 20494333.
  29. Cooper N, Bussel JB. The long-term impact of rituximab for childhood immune
    thrombocytopenia. Curr Rheumatol Rep. 2010 Apr;12(2):94-100. Review. PubMed PMID: 20425017.
  30. Bussel JB. Update on eltrombopag for ITP. Oncology (Williston Park). 2009 Nov
    30;23(13):1177-8. PubMed PMID: 20043469.
  31. Bussel JB. Traditional and new approaches to the management of immune
    thrombocytopenia: issues of when and who to treat. Hematol Oncol Clin North Am.
    2009 Dec;23(6):1329-41. Review. PubMed PMID: 19932437.
  32. Peerschke EI, Andemariam B, Yin W, Bussel JB. Complement activation on
    platelets correlates with a decrease in circulating immature platelets in
    patients with immune thrombocytopenic purpura. Br J Haematol. 2010
    Feb;148(4):638-45. Epub 2009 Nov 19. PubMed PMID: 19925495.
  33. Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB,
    Chong BH, Cines DB, Gernsheimer TB, Godeau B, Grainger J, Greer I, Hunt BJ,
    Imbach PA, Lyons G, McMillan R, Rodeghiero F, Sanz MA, Tarantino M, Watson S,
    Young J, Kuter DJ. International consensus report on the investigation and
    management of primary immune thrombocytopenia. Blood. 2010 Jan 14;115(2):168-86. Epub 2009 Oct 21. Review. PubMed PMID: 19846889.
  34. Psaila B, Petrovic A, Page LK, Menell J, Schonholz M, Bussel JB. Intracranial
    hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40
    cases. Blood. 2009 Nov 26;114(23):4777-83. Epub 2009 Sep 18. PubMed PMID:
    19767509; PubMed Central PMCID: PMC2786288.
  35. Marks KM, Clarke RM, Bussel JB, Talal AH, Glesby MJ. Risk factors for
    thrombocytopenia in HIV-infected persons in the era of potent antiretroviral
    therapy. J Acquir Immune Defic Syndr. 2009 Dec;52(5):595-9. PubMed PMID:
    19734800; PubMed Central PMCID: PMC2787779.
  36. Sharma G, Nesin M, Feuerstein M, Bussel JB. Maternal and neonatal
    characteristics associated with neonatal neutropenia in hypertensive pregnancies.
    Am J Perinatol. 2009 Oct;26(9):683-9. Epub 2009 May 20. PubMed PMID: 19670129.
  37. Chen K, Xu W, Wilson M, He B, Miller NW, Bengtén E, Edholm ES, Santini PA,
    Rath P, Chiu A, Cattalini M, Litzman J, B Bussel J, Huang B, Meini A, Riesbeck K,
    Cunningham-Rundles C, Plebani A, Cerutti A. Immunoglobulin D enhances immune surveillance by activating antimicrobial, proinflammatory and B cell-stimulating programs in basophils. Nat Immunol. 2009 Aug;10(8):889-98. Epub 2009 Jun 28. PubMed PMID: 19561614; PubMed Central PMCID: PMC2785232.
  38. DiMaggio D, Anderson A, Bussel JB. Cytomegalovirus can make immune
    thrombocytopenic purpura refractory. Br J Haematol. 2009 Jun;146(1):104-12. Epub 2009 May 9. PubMed PMID: 19438507.
  39. Cohn CS, Bussel JB. Romiplostim: a second-generation thrombopoietin agonist.
    Drugs Today (Barc). 2009 Mar;45(3):175-88. Review. PubMed PMID: 19436840.
  40. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009 Jun 25;113(26):6511-21. Epub 2009 Apr 24. Review. PubMed PMID: 19395674; PubMed Central PMCID: PMC2710913.
  41. Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, Kuhne T, Ruggeri M, George JN. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura (ITP) of adults and children: report from an international working group. Blood, 2009; 113(11): 2386-93.
  42. Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury Db, Mayer B, Stone N, Arning M. Eltrombopag Increases Platelet Counts and Reduces Bleeding During Treatment of Chronic Idiopathic Thrombocytopenic Purpura (ITP): A Randomized, Double Blind, Placebo-controlled Study. Lancet, 2009; 373(9664): 641-8.
  43. Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB. Of Mice and Men: an Open Label Pilot Study for Treatment of Immune Thrombocytopenic Purpura (ITP) by an Inhibitor of Syk. Blood, 2009; 113(14): 3154-60.
  44. Bussel JB, Kuter D, Pullarkat VA, Lyons R, Guo M, Nichol J. Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood, 2009; 113(10): 2161-71.
  45. Stasi R, Sarpatwari A, Segal JB, Osborn J, Evangelista ML, Cooper N, Provan D, Newland A, Amadori S, Bussel JB. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura. A systematic review. Blood, 2009; 113(6): 1231-40.
  46. Mueller BU, Bennett CM, Feldman HA, Bussel JB, Abshire TC, Moore TB, Sawaf H, Loh ML, Rogers ZR, Glader BE, McCarthy MC, Mahoney DH, Olson TA, Feig SA, Lorenzana AN, Mentzer WC, Buchanan GR, Neufeld EJ; for the Pediatric Rituximab/ITP Study Group, the Glaser Pediatric Research Network. One year follow-up of children and adolescents with chronic immune thrombocytopenic purpura (ITP) treated with rituximab. Pediatric Blood & Cancer, 2009; 52(2): 259-62.
  47. DiMaggio D, Anderson A, Bussel JB. Cytomegalovirus Causes Refractory Immune Thrombocytopenic Purpura. British Journal of Haematology, 2009; 146(1): 104-12.
  48. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP Syndrome: a diverse set of disorders with different immune mechanisms. Blood, 2009; 113(26): 6511-21.
  49. Sharma G, Nesin M, Feuerstein M, Bussel JB. Maternal and Neonatal Characteristics Associated with Neonatal Neutropenia in Hypertensive Pregnancies. American Journal of Perinatology, 2009.
  50. Hasan A, Michel M, Patel V, Stasi R, Cunningham Rundles S, Leonard J, Bussel JB. Repeated courses of rituximab in chronic ITP: three different regimens. Am J Heme, 2009.
  51. Levy B, Arnason JE, Bussel JB. The use of second-generation thrombopoietic
    agents for chemotherapy-induced thrombocytopenia. Curr Opin Oncol. 2008
    Nov;20(6):690-6. Review. PubMed PMID: 18841052.
  52. Wasserstrom H, Bussel J, Lim LC, Cunningham-Rundles C. Memory B cells and
    pneumococcal antibody after splenectomy. J Immunol. 2008 Sep 1;181(5):3684-9.
    PubMed PMID: 18714044; PubMed Central PMCID: PMC2919219.
  53. Psaila B, Bussel JB. Fc receptors in immune thrombocytopenias: a target for
    immunomodulation? J Clin Invest. 2008 Aug;118(8):2677-81. PubMed PMID: 18654670; PubMed Central PMCID: PMC2483687.
  54. Bussel JB, Marks KM. How effective is eltrombopag for the treatment of
    thrombocytopenia in patients with HCV infection? Nat Clin Pract Gastroenterol
    Hepatol. 2008 Aug;5(8):424-5. Epub 2008 Jul 8. PubMed PMID: 18607406.
  55. Psaila B, Bussel JB. Refractory immune thrombocytopenic purpura: current
    strategies for investigation and management. Br J Haematol. 2008
    Oct;143(1):16-26. Review. PubMed PMID: 18573111.
  56. Kobos R, Bussel JB. Overview of thrombopoietic agents in the treatment of
    thrombocytopenia. Clin Lymphoma Myeloma. 2008 Feb;8(1):33-43. Review. PubMed PMID: 18501086.
  57. Yu J, Heck S, Patel V, Levan J, Yu Y, Bussel JB, Yazdanbakhsh K. Defective
    circulating CD25 regulatory T cells in patients with chronic immune
    thrombocytopenic purpura. Blood. 2008 Aug 15;112(4):1325-8. Epub 2008 Apr 17.
    PubMed PMID: 18420827; PubMed Central PMCID: PMC251513.
  58. McMillan R, Bussel JB, George JN, Lalla D, Nichol JL. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. American Journal of Hematology, 2008; 83(2): 150-4.
  59. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, George JN, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet, 2008; 371: 395-403.
  60. Patel VL, Schwartz J, Bussel JB. The Effect of Blocking the CD40-CD40ligand Pathway in Patients with Immune Thrombocytopenic Purpura. British Jounral of Haem, 2008; 141: 545-48.
  61. Mathias SD, Gao SK, Miller KL, Cella D, Snyder C, Turner R, Wu A, Bussel JB, George JN, McMIllan R, Wysocki DK, Nichol JN. Impact of chronic immune thrombocytopenic purpura (ITP) on health-related quality of life: a conceptual model starting with the patient perspective. Health and Quality of Life Outcomes, 2008; 6:13.
  62. Yu J, Heck S, Patel V, Levan J, Yu Y, Bussel JB, Yazdanbakhsh K. Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood, 2008; 112(4): 1325-28.
  63. Wasserstrom H, Bussel JB, Lim LCL, Cunningham-Rundles C. Memory B cells and Antibody to Pneumococcal Vaccine in Splenectomized Subjects. J Immuno, 2008; 181(5): 3684-9.
  64. Patel VL, Schwartz J, Bussel JB. The effect of anti-CD40 ligand in immune
    thrombocytopenic purpura. Br J Haematol. 2008 May;141(4):545-8. Epub 2008 Mar 12. PubMed PMID: 18341638.
  65. McMillan R, Bussel JB, George JN, Lalla D, Nichol JL. Self-reported
    health-related quality of life in adults with chronic immune thrombocytopenic
    purpura. Am J Hematol. 2008 Feb;83(2):150-4. PubMed PMID: 17722072.
  66. Mathias SD, Gao SK, Miller KL, Cella D, Snyder C, Turner R, Wu A, Bussel JB,
    George JN, McMillan R, Wysocki DK, Nichol JL. Impact of chronic Immune
    Thrombocytopenic Purpura (ITP) on health-related quality of life: a conceptual
    model starting with the patient perspective. Health Qual Life Outcomes. 2008 Feb
    8;6:13. PubMed PMID: 18261217; PubMed Central PMCID: PMC2275726.
  67. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM,
    Aledort LM, George JN, Kessler CM, Sanz MA, Liebman HA, Slovick FT, de Wolf JT,
    Bourgeois E, Guthrie TH Jr, Newland A, Wasser JS, Hamburg SI, Grande C, Lefrère F, Lichtin AE, Tarantino MD, Terebelo HR, Viallard JF, Cuevas FJ, Go RS, Henry DH, Redner RL, Rice L, Schipperus MR, Guo DM, Nichol JL. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008 Feb 2;371(9610):395-403. PubMed PMID: 18242413.
  68. Kalpatthi R, Bussel JB. Diagnosis, pathophysiology and management of children
    with refractory immune thrombocytopenic purpura. Curr Opin Pediatr. 2008 Feb;20(1):8-16. Review. PubMed PMID: 18197033.
  69. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J,
    Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007 Nov 29;357(22):2237-47. PubMed PMID: 18046028.
  70. Andemariam B, Psaila B, Bussel JB. Novel thrombopoietic agents. Hematology Am Soc Hematol Educ Program. 2007:106-13. Review. PubMed PMID: 18024617.
  71. Zhang L, Radigan L, Salzer U, Behrens TW, Grimbacher B, Diaz G, Bussel J,
    Cunningham-Rundles C. Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical andimmunologic outcomes in heterozygotes. J Allergy Clin Immunol. 2007
    Nov;120(5):1178-85. PubMed PMID: 17983875; PubMed Central PMCID: PMC2908504.
  72. Bussel JB, Primiani A. Fetal and neonatal alloimmune thrombocytopenia:
    progress and ongoing debates. Blood Rev. 2008 Jan;22(1):33-52. Epub 2007 Nov 5. PubMed PMID: 17981381.
  73. Godeau B, Provan D, Bussel J. Immune thrombocytopenic purpura in adults. Curr
    Opin Hematol. 2007 Sep;14(5):535-56. Review. PubMed PMID: 17934364.
  74. Andemariam B, Bussel J. New therapies for immune thrombocytopenic purpura.
    Curr Opin Hematol. 2007 Sep;14(5):427-31. Review. PubMed PMID: 17934347.
  75. Boruchov DM, Gururangan S, Driscoll MC, Bussel JB. Multiagent induction and
    maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood. 2007 Nov 15;110(10):3526-31. Epub 2007 Aug 13. PubMed PMID: 17698634.
  76. Mathias SD, Bussel JB, George JN, McMillan R, Okano GJ, Nichol JL. A
    disease-specific measure of health-related quality of life in adults with chronic
    immune thrombocytopenic purpura: psychometric testing in an open-label clinical
    trial. Clin Ther. 2007 May;29(5):950-62. PubMed PMID: 17697914.
  77. Berkowitz RL, Lesser ML, McFarland JG, Wissert M, Primiani A, Hung C, Bussel
    JB. Antepartum treatment without early cordocentesis for standard-risk alloimmune thrombocytopenia: a randomized controlled trial. Obstet Gynecol. 2007 Aug;110(2 Pt 1):249-55. PubMed PMID: 17666597.
  78. Psaila B, Bussel JB. Immune thrombocytopenic purpura. Hematol Oncol Clin
    North Am. 2007 Aug;21(4):743-59, vii. Review. PubMed PMID: 17666288.
  79. Hervé M, Isnardi I, Ng YS, Bussel JB, Ochs HD, Cunningham-Rundles C, Meffre
    E. CD40 ligand and MHC class II expression are essential for human peripheral B
    cell tolerance. J Exp Med. 2007 Jul 9;204(7):1583-93. Epub 2007 Jun 11. PubMed
    PMID: 17562816; PubMed Central PMCID: PMC2118633.
  80. Tarantino MD, Bussel JB, Cines DB, McCrae KR, Gernsheimer T, Liebman HA, Wong WY, Kulkarni R, Grabowski E, McMillan R. A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP). Blood. 2007 Jun 15;109(12):5527; author reply 5528. PubMed PMID: 17554071.
  81. Bussel JB. Novel thrombopoietic agents: preliminary activity, potential
    benefit. J Support Oncol. 2007 Apr;5(4 Suppl 2):63-84. Review. PubMed PMID:
    17550056.
  82. Page LK, Psaila B, Provan D, Michael Hamilton J, Jenkins JM, Elish AS, Lesser
    ML, Bussel JB. The immune thrombocytopenic purpura (ITP) bleeding score:
    assessment of bleeding in patients with ITP. Br J Haematol. 2007
    Jul;138(2):245-8. Epub 2007 Jun 3. PubMed PMID: 17542983.
  83. Bussel JB, Giulino L, Lee S, Patel VL, Sandborg C, Stiehm ER. Update on
    therapeutic monoclonal antibodies. Curr Probl Pediatr Adolesc Health Care. 2007
    Apr;37(4):118-35. Review. PubMed PMID: 17434008Mathias SD, Bussel JB, George JN, McMillan R, Okano GJ, Nichol JL. A disease-specific measure of health-related quality of life for use in adults with immune thrombocytopenic purpura: its development and validation. Health Qual Life Outcomes, 2007; 5: 11.
  84. Page L, Psaila B, Provan D, Hamilton JM, Jenkins JM, Elish AS, Lesser ML, Bussel JB. The ITP Bleeding Score (IBLS): Assessment of Bleeding in Patients with Immune Thrombocytopenic Purpura (ITP). British Journal of Haematology, 2007; 138(2): 245-8.
  85. Berkowitz RL, Lesser ML, McFarland JG, Wissert M, Primiani A, Hung C, and Bussel JB. An antepartum treatment trial without early cordocentesis for "standard risk" alloimmune thrombocytopenia: A randomized controlled trial. Obstetrics & Gynecology, 2007; 110 (2 Pt 1): 249-55.
  86. Boruchov DM, Gururangan S, Driscoll MC, Bussel JB. Multi-agent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood, 2007; 110(10): 3526-31.
  87. Zhang L, Radigan L, Salzer U, Behrens T, Grimbacher B, Diaz G, Bussel JB, and Cunningham-Rundles C. Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in Common Variable Immunodeficiency: Clinical and Immunologic Outcomes in Heterozygotes. Journal of Allergy and Clinical Immunology, 2007; 120: 1178-85.
  88. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM. Eltrombopag, an Oral Platelet Growth Factor, for the Treatment of Patients with Chronic Idiopathic Thrombocytopenic Purpura. NEJM, 2007; 357(22): 2237-47.
  89. Bussel JB, Tarantino MD, Nalysnyk L, Fahrbach K, Sercus B, Genereux M, and Sinclair C. Efficacy and safety of intravenous rhesus 0 human immune globulin (IV RhIG) and standard polyclonal intravenous immune globulins (IVIG) in the treatment of immune thrombocytopenic purpura: A systematic review. U.S. Hematology Touch Briefings, 2007; 3-7.
  90. Bussel JB, Cines DB. Introduction: Immune thrombocytopenic purpura. Curr Opin Hematol, 2007; 14(5): 510.
  91. Andemariam B, Bussel J. New therapies for immune thrombocytopenic purpura. Curr Opin Hematol, 2007; 14(5): 427-31.
  1. Bussel JB. Novel thrombopoietic agents: preliminary activity, potential benefit. J Support Oncol, 2007; 5 (4 Suppl 2): 63-84.
  2. Godeau B, Provan D, Bussel JB. Immune thrombocytopenic purpura in adults. Curr Opin Hematol, 2007; 14(5): 535-556.
  3. Bussel JB, Hanna K, and the IGIV-C in ITP Study Group. Safety and tolerability of a novel chromatography-based intravenous immunoglobulin when administered at a high infusion rate in patients with immune thrombocytopenic purpura (ITP). American Journal of Hematology, 2007; 82: 192-198.
  4. Scaradavou A, Cunningham-Rundles S, Ho JL, Folman C, Doo H, and Bussel JB. Superior effect of intravenous anti-D compared to IV gammaglobulin in the treatment of HIV-thrombocytopenia: results of a small, randomized prospective comparison. American Journal of Hematology, 2007; 82(5): 335-41.
  5. Giulino LB, Bussel JB, Neufeld EJ, and the Pediatric and Platelet Immunology Committees of the TMH clinical trial network. Treatment with Rituximab in benign and malignant hematologic disorders in children. Journal of Pediatrics, 2007; 150(4): 338-44.

Honors and Awards

HONORS AND AWARDS

  1. Voted one of New York Magazine's Best Doctors, 2008-2012
  2. Voted one of New York City's Super Doctors in Pediatrics, 2009-2012
  3. Voted one of Castle Connolly's America's Top Doctors, 2007
  4. Voted one of Castle Connolly's America's Top Doctors, 2003
  5. Who's Who in America 2007
  6. Speaker, The Henry Kunkel Society 11th Meeting, Kunkel Society Symposium, Rockefeller University, New York, New York, 2003
  7. Selection as 1 of 15 representatives of American Society of Hematology for SPARKII, 2003
  8. Abstract Reviewer for ASH Platelet Section, 2003
  9. Chairman, Corporate Symposium on ITP at ASH (Super Friday), 2003
  10. Voted one of New York Magazine's Best Doctors, 2003
  11. Voted one of New York Magazine's Best Doctors, 2002
  12. Voted one of Castle Connolly's America's Top Doctors, 2002
  13. Chairman, Corporate Symposium on ITP at ASH (Super Friday), 2002
  14. Voted one of New York Magazine's Best Doctors, 2001
  15. Voted one of Castle Connolly's America's Top Doctors, 2001
  16. Abstract Reviewer for ASH Platelet Section, 2001
  17. Chairman, Corporate Symposium on ITP at ASH (Super Friday), 2001
  18. Abstract Reviewer for ASH Platelet Section, 2000
  19. Chair, Education Session on Platelets at ASH, 2000
  20. Chairman, Corporate Symposium on ITP at ASH (Super Friday), 2000
  21. Chairman, Corporate Symposium on ITP at ASH (Super Friday), 1999
  22. Chairman of ITP Meeting to Discuss Splenectomy Sparing Strategy, Boca Raton, Florida, 1998
  23. Alpha Award of the American Blood Resources Association for Contributions in Immunohematology, 1998
  24. 22nd Ratnoff Professor of Hematology at Case Western, 2008